Inectolizumab and steroids for first NMOSD attack
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a new medicine called inectolizumab, combined with optimized steroid therapy, for people having their first attack of neuromyelitis optica spectrum disorder (NMOSD). The goal is to see if this combination better controls the disease and prevents future attacks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of NMOSD with a positive AQP4 antibody test, and this is your first attack.
- You should be between 18 and 65 years old.
- You must be able to walk on your own or with some help (EDSS score of 7.5 or less).
- If you are a woman of childbearing age, you need a negative pregnancy test and agree to use effective birth control during the study.
- You must not have taken certain immune-suppressing drugs (like rituximab, azathioprine, or methotrexate) within specific timeframes before starting.
- You cannot have active infections like hepatitis B or C, HIV, or a recent live vaccine (except shingles vaccine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called efgartigimod for people having a sudden worsening of NMOSD symptoms. It targets a protein to reduce attack severity and is given alongside standard care.
This trial tests whether a slower or faster reduction of steroid pills, combined with the drug inebilizumab, is more effective for people with NMOSD (a rare autoimmune disease affecting the nerves). The study aims to find the best way to manage treatment after an attack.
This trial studies inebilizumab to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are having an acute attack. It aims to reduce ongoing nerve damage and disability after a recent flare, alongside standard steroid treatment.
This trial studies whether inebilizumab can reduce illness activity in children with neuromyelitis optica spectrum disorder (NMOSD), a condition that can cause attacks affecting the eyes and spinal cord. It focuses on kids who have had recent relapses, meaning symptoms came back or worsened.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
This trial tests a new drug called IMC-002 for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4+). It aims to see if IMC-002 is safe and effective at preventing attacks.
Hear when a new Neuromyelitis Optica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.